Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer - PubMed (original) (raw)

Clinical Trial

Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer

W Yu et al. Ann Surg. 1998 Sep.

Abstract

Objective: Surgeons have postulated on numerous occasions that cancer resection may participate in the dissemination of a malignancy. This randomized trial sought to determine whether a large volume of chemotherapy solution used perioperatively to flood the peritoneal cavity could eliminate microscopic residual disease and thereby improve survival of patients with gastric cancer.

Summary background data: Surgical treatment failures in patients with gastric cancer are confined to the abdomen in most patients. Resection site and peritoneal surface spread, along with liver metastases, are the most common areas of recurrence. Survival and quality of life of patients with gastric cancer would be improved if disease progression at these anatomic sites was reduced.

Methods: In a prospective randomized trial of 248 patients, intraperitoneal mitomycin C on day 1 and intraperitoneal 5-fluorouracil on days 2 through 5 were administered after gastric cancer resection. Patients who were thought to have stage II or stage III disease were randomized after resection to surgery alone versus surgery plus early postoperative intraperitoneal chemotherapy. After final pathologic examinations, there were 39 patients with stage I, 50 with stage II 95 with stage III, and 64 with resected stage IV cancer.

Results: The 5-year survival of the surgery-only group was 29.3%, and the surgery-plus-intraperitoneal chemotherapy group was 38.7% (p = 0.219). In a subset analysis, the patients with stage I, stage II, and stage IV disease showed no statistically significant difference in survival. The 5-year survival rate of patients with stage III disease who underwent surgery only was 18.4% versus a survival rate of 49.1% for patients who underwent surgery plus intraperitoneal chemotherapy (p = 0.011).

Conclusions: In a subset analysis, patients with stage III gastric cancer have shown a statistically significant improvement in survival when treated with perioperative intraperitoneal chemotherapy. Further studies in patients with gastric cancer with surgically directed chemotherapy are suggested.

PubMed Disclaimer

Similar articles

• Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: results of a prospective randomized trial.
  Yu W, Whang I, Chung HY, Averbach A, Sugarbaker PH. Yu W, et al. World J Surg. 2001 Aug;25(8):985-90. doi: 10.1007/s00268-001-0067-7. World J Surg. 2001. PMID: 11571980 Clinical Trial.
• Early postoperative intraperitoneal chemotherapy with mitomycin C, 5-fluorouracil and cisplatin for advanced gastric cancer.
  Noh SH, Yoo CH, Chung HC, Roh JK, Shin DW, Min JS. Noh SH, et al. Oncology. 2001;60(1):24-30. doi: 10.1159/000055292. Oncology. 2001. PMID: 11150904
• A review of adjuvant therapy for resected primary gastric cancer with an update on Taegu's phase III trial with intraperitoneal chemotherapy.
  Yu W. Yu W. Eur J Surg Oncol. 2006 Aug;32(6):655-60. doi: 10.1016/j.ejso.2006.03.010. Epub 2006 Apr 18. Eur J Surg Oncol. 2006. PMID: 16618532 Review.
• Upper abdominal stop-flow perfusion as a neo and adjuvant hypoxic regional chemotherapy for resectable gastric carcinoma. A prospective randomized clinical trial.
  Lygidakis NJ, Sgourakis G, Aphinives P. Lygidakis NJ, et al. Hepatogastroenterology. 1999 May-Jun;46(27):2035-8. Hepatogastroenterology. 1999. PMID: 10430393 Clinical Trial.
• Palliation with a glimmer of hope: management of resectable gastric cancer with peritoneal carcinomatosis.
  Sugarbaker PH, Yonemura Y. Sugarbaker PH, et al. Hepatogastroenterology. 2001 Sep-Oct;48(41):1238-47. Hepatogastroenterology. 2001. PMID: 11677938 Review.

Cited by

• A 26-year-old female with metastatic primary gastrointestinal malignancy presenting as menorrhagia.
  Khan M, Bhatti RP, Mukherjee S, Ali AM, Gilman AD, Mirrakhimov AE, Iroegbu N. Khan M, et al. J Gastrointest Oncol. 2015 Apr;6(2):E21-5. doi: 10.3978/j.issn.2078-6891.2014.080. J Gastrointest Oncol. 2015. PMID: 25830046 Free PMC article.
• Gastric carcinoma.
  Phan AT, Ajani JA. Phan AT, et al. Curr Oncol Rep. 2004 May;6(3):192-8. doi: 10.1007/s11912-004-0049-7. Curr Oncol Rep. 2004. PMID: 15066230 Review.
• Surgical management of carcinomatosis from colorectal cancer.
  Sugarbaker PH. Sugarbaker PH. Clin Colon Rectal Surg. 2005 Aug;18(3):190-203. doi: 10.1055/s-2005-916280. Clin Colon Rectal Surg. 2005. PMID: 20011302 Free PMC article.
• Guidelines for the management of oesophageal and gastric cancer.
  Allum WH, Griffin SM, Watson A, Colin-Jones D; Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland; British Society of Gastroenterology; British Association of Surgical Oncology. Allum WH, et al. Gut. 2002 Jun;50 Suppl 5(Suppl 5):v1-23. doi: 10.1136/gut.50.90005.v1. Gut. 2002. PMID: 12049068 Free PMC article. No abstract available.
• Clinicopathological analysis of patients with gastric cancer in 1200 cases.
  Niu WX, Qin XY, Liu H, Wang CP. Niu WX, et al. World J Gastroenterol. 2001 Apr;7(2):281-4. doi: 10.3748/wjg.v7.i2.281. World J Gastroenterol. 2001. PMID: 11819775 Free PMC article. No abstract available.

References

1. 1. Eur J Surg. 1995 Aug;161(8):581-6 - PubMed
2. 1. Ann Oncol. 1994;5 Suppl 3:69-72 - PubMed
3. 1. J Surg Oncol. 1996 Jun;62(2):128-34 - PubMed
4. 1. Cancer Treat Res. 1996;82:289-309 - PubMed
5. 1. Surg Gynecol Obstet. 1952 Apr;94(4):401-25 - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • PubMed Central
  • Wolters Kluwer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information